急性髓系白血病T细胞受体疗法的当前进展
本综述聚焦急性髓系白血病的T细胞受体(TCR)疗法,讨论其靶抗原、TCR鉴定策略、临床前TCR T细胞开发及早期临床试验结果,并探讨改善功能疗效与安全性的分子设计。
要点
- TCR疗法可靶向经HLA分子呈递的胞内抗原肽,为AML提供CAR T细胞之外的细胞治疗选择。
- 综述涵盖WT1、PRAME及次要组织相容性抗原HA-1等靶点的早期临床试验结果。
- 综述讨论创新分子设计以改善功能疗效、减轻安全性担忧并克服HLA限制。
核心结论
- TCR疗法有望成为AML免疫治疗不可或缺的组成部分。
研究设计与样本
- 综述:探讨AML中靶向的抗原、TCR鉴定的多种方法与策略以及临床前TCR T细胞开发。
主要发现
- 靶向单一表面抗原的CAR T细胞在B细胞淋巴细胞白血病、淋巴瘤和多发性骨髓瘤中显示出显著疗效。
- AML因白血病免疫表型异质性广泛表达及正常髓系细胞上亦存在表面抗原靶点,对CAR T细胞有效性构成巨大障碍。
- TCR疗法可靶向经HLA分子呈递的胞内抗原肽,其用于AML的开发正通过临床前研究和成功的临床试验快速推进。
- 综述重点介绍了靶向Wilms瘤基因1、黑色素瘤优先表达抗原及次要组织相容性抗原HA-1的早期临床试验具体结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell receptor (TCR) therapies are a promising modality for the treatment of cancers, with significant efforts being directed toward acute myeloid leukemia (AML), a particularly challenging disease. Chimeric antigen receptor (CAR) T cells targeting single surface antigens have shown remarkable efficacy for B-cell lymphoblastic leukemia, lymphomas, and multiple myeloma. However, AML presents formidable obstacles to the effectiveness of CAR T cells because of the widespread expression of heterogenous leukemia immunophenotypes and surface antigen targets additionally present on normal myeloid cells. TCR therapies are an evolving field of cell therapies that allow targeting intracellular antigenic peptides presented via HLA molecules. The development of TCR therapy for AML is progressing rapidly through preclinical research and successful clinical trials. This review specifically explores the antigens targeted in AML, the diverse methodologies and strategies used in TCR identification, and preclinical TCR T-cell development. The review also discusses innovative molecular designs to improve functional efficacy, mitigate safety concerns, and overcome HLA restrictions. Specific outcomes of early clinical trials targeting important antigens Wilms tumor gene 1, preferentially expressed antigen in melanoma, and minor histocompatibility antigen HA-1 are also highlighted. Ultimately, this review underscores why TCR therapy is poised to become an indispensable component of AML immunotherapy.
引用
- Gore S, Blyth E, Bleakley M, et al. Current developments in T-cell receptor therapy for acute myeloid leukemia. Blood Adv. 2025. PMID: 39813621. doi:10.1182/bloodadvances.2024014105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。